Marinus Pharmaceuticals Inc. (MRNS)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XFRA 
Shareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
MRNS SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / July 7, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
An Inquiry Into Marinus Pharmaceuticals Inc Is Launched By The Schall Law Firm, Encouraging Impacted Investors To Commence Dialogue
LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
August 5, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against MRNS
NEW YORK, NY / ACCESSWIRE / July 6, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
The Schall Law Firm Initiates An Examination Into Marinus Pharmaceuticals Inc And Urges Affected Investors To Establish Contact
LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Marinus Pharmaceuticals, Inc. Class Action: Levi & Korsinsky Reminds Marinus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2024 - MRNS
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc.(MRNS) Shareholders
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Shareholders of Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors in Marinus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 5, 2024 to Discuss Your Rights - MRNS
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
MRNS SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Marinus Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. ("Marinus" or "the Company") (NASDAQ:MRNS) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Marinus securities between March 17, 2021 and May 7, 2024, inclusive (the "Class Period").
